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Abstract  
Alcoholic liver disease is a global health issue. This wide-ranging entity 
encompasses a distinct clinical syndrome induced by alcohol consumption known as 
acute alcoholic hepatitis. The clinical spectrum ranges from asymptomatic to 
symptomatic presentation with analytical changes, hepatic failure and death. With a 28-
day mortality of up to 50%, treatment is essential. Within the various therapeutic agents 
proposed for treatment of acute alcoholic hepatitis, corticosteroids are still the first 
option in clinical practice. Nevertheless, it is not effective in all cases. In those patients 
defined as non-responders, corticotherapy does not improve long term survival, and thus 
a new approach to treatment is necessary.  It is in these cases that we may look to 
hepatic transplant as a possible treatment route.  
 
    
 Hepatic transplant in patients with acute alcoholic hepatitis, however, has proven 
quite controversial. There is a reluctance to allot the scarce organs available to patients 
whom the public often views as responsible for their own disease. The concern that 
patients would relapse post-transplant has contributed to the implementation of a 6 
month alcohol abstinence period still required for patients to be considered for 
transplant in some countries. Conversely, new studies point away from the use of this 6 
month rule and instead enforce the implementation of selecting patients for transplant 
based on other criteria of greater importance to outcome.     
 We report the case of a 56 year old male presenting with acute alcoholic 
hepatitis, non-responder to therapy with corticosteroids, that was posteriorly proposed 
for hepatic transplant. 
Key Words: acute alcoholic hepatitis, hepatic transplant, corticosteroids, non-
responder, alcoholic abstinence. 
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Resumo 
A doença hepática alcoólica é um problema de saúde global. A hepatite aguda 
alcoólica é caracterizada por ser uma síndrome clínica distinta induzida pelo consumo 
de álcool. O espectro clínico vai desde um estado assintomático até sintomas associados 
a alterações analíticas, insuficiência hepática e morte. Com uma mortalidade aos 28 dias 
de até 50%, um tratamento eficaz é essencial. Dentro dos vários agentes terapêuticos 
propostos para o tratamento, os corticosteróides constituem ainda a primeira opção na 
prática clínica. No entanto, a corticoterapia não é eficaz em todos os casos. Nos doentes 
definidos como não-respondedores, a corticoterapia não aumenta a sobrevida a longo 
prazo e, assim, uma nova abordagem terapêutica é necessária. Consequentemente, o 
transplante hepático torna-se nestes casos uma opção atraente.    
 O transplante hepático em doentes com hepatite aguda alcoólica, no entanto, 
permanece um assunto bastante controverso. Existe uma relutância em disponibilizar 
órgãos (que são escassos) para transplante a doentes que o público geralmente 
percepciona como tendo infligido em si a sua doença. A preocupação de que os doentes 
poderão vir a sofrer de uma recaída após o transplante, contribuiu para a implementação 
de um período obrigatório de 6 meses de abstinência alcoólica, ainda necessária para 
que tais doentes sejam considerados para transplante hepático em alguns países. 
Contudo, vários estudos recentes têm vindo a valorizar a criteriosa selecção de doentes 
candidatos a transplante hepático em detrimento da regra dos seis meses.  
 Reportamos o caso clínico de um doente de 56 anos de idade que se apresentou 
com hepatite aguda alcoólica, não-respondedor à corticoterapia, sendo posteriormente        
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submetido a transplante hepático. Um resumo mais detalhado pode ser consultado no 
Apêndice. 
Palavras-chave: hepatite aguda alcoólica, transplante hepático, corticosteróides, não-
respondedor, abstinência alcoólica. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
Liver transplant in alcoholic hepatitis 
Introduction 
With increasing alcohol consumption worldwide, alcoholic liver disease (ALD) 
has become a significant global health concern.
1 
According to the World Health 
Organization (WHO), alcohol consumption is the third leading cause of premature death 
and disability in the European Union and can be attributed to up to 9.2% of all disability 
adjusted life years.
2-4
  
Acute alcoholic hepatitis (AAH) is a distinct clinical syndrome induced by 
alcohol consumption with a particularly poor prognosis with a 28-day mortality ranging 
from 30%-50%.
5 
This syndrome encompasses a clinical spectrum ranging from 
asymptomatic to symptomatic forms with analytical changes, hepatic failure and death. 
The actual prevalence of AAH is difficult to gauge because it can be completely 
asymptomatic and many patients are underdiagnosed, though a prevalence of 
approximately 20% was observed in a cohort of 1604 patients with alcoholism who 
underwent a hepatic biopsy.
5 
In addition, it is estimated that about 35% of alcoholics 
suffer from AAH, most cases occurring before the age of 60 years.
5-6
   
 In general, the risk of liver disease is associated with the pattern of drinking, the 
type of drink consumed and the amount of alcohol consumed.
2,5,7
 A daily intake of 
alcohol for 10-12 years with doses in excess of 40-80 g/day for males and  20-40 g/day 
for females are generally needed to cause alcoholic liver disease.
8  
However, current 
European guidelines refer that even the ingestion of small amounts of alcohol (< 25 
g/day) may be enough to induce alcoholic liver disease.
9
 Ethnicity,
2,5,10 
as well as other 
risk factors including obesity
5
, iron overload, concomitant infection with viral hepatitis 
and genetic factors are also implied.
2
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The diagnosis of ALD is based on a combination of features, including a history 
of significant alcohol intake, clinical evidence of liver disease, and supporting 
laboratory abnormalities.
2,8 
AAH is associated with a broad clinical picture including 
asthenia, pain in the right hypochondrium, fever, tachycardia and frequently jaundice. 
Typically, the ratio of aspartate aminotransferase to alanine aminotransferase 
(ASAT/ALAT) is approximately 2:1.
2
 Other common laboratory abnormalities include 
hyperbilirubinemia, leukocytosis and anemia.
2,8
 In addition to the laboratory 
characteristics common to all forms of ALD, AAH is typically associated with elevated 
concentrations of gamma-glutamyl transpeptidase and of alkaline phosphatase.
11
  
In addition to nutritional support and ensuring alcohol abstinence,
2,8,12-13
 other 
therapeutic agents such as corticosteroids,
14-15
 anti-oxidant therapy,
12,16-18
 
pentoxifylline,
19-20 
TNF-α antibodies, propylthiouracil, colchicine, S-adenosyl-L-
methionine,
8,21-23
 and even  molecular adsorbent recirculating system (MARS)
21-22,24-25
 
have been proposed. Of these therapies, only corticosteroids have found a place in 
regular practice, although even here, the data on their efficacy are controversial. 
Pentoxifylline and MARS do, however, show promise in specific cases. In addition, the 
association of N-acetylcysteine to corticosteroid treatment has recently been found to 
improve short term survival, and may be considered as an adjunct to standard 
treatment.
18 
         
 As a result, standard medical treatment for patients with AAH may include the 
administration of corticosteroids to those who have a Maddrey discriminant function 
(DF) greater than or equal to 32, or more recently, a Glasgow Alcoholic Hepatitis Score 
(GAHS) greater than or equal to 9.
2,8,21,26
  The Lille score will posteriorly evaluate the 
response to corticosteroids after 7 days, giving an indication of which patients will 
respond to and therefore benefit from maintenance of the corticoid therapy.
27-28
 Patients 
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who do not respond to corticotherapy have a poor survival rate.
29
 Consequently, new 
strategies are needed in order to address these cases. 
Chronic liver disease with progression to cirrhosis and its inherent complications 
are the second most common reason for liver transplantation in the United States and 
Europe.
30-31
 It is usual practice in most programs in North America and Europe to 
require patients with ALD to be abstinent for 6 months prior to transplantation.
22,32 
However, the United Network for Organ Sharing (UNOS) and the French Consensus 
Conference do not consider it to be a rule since 2005.
29,33 
For patients with severe 
alcoholic hepatitis who do not respond to corticosteroid treatment, deferring 
transplantation for six months may not be an option due to precocious mortality.
22 
In the following report the case of a male patient aged 56 years who presented 
with AAH, non-responder to corticotherapy, with progression to liver failure and 
posteriorly subjected to hepatic transplant, will be addressed.  The role of hepatic 
transplant in context of alcohol intake will be discussed as well as the ethical 
implications inherent to the realization of this as of yet nonconsensual procedure. 
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Case Report 
A 56-year-old autonomous male, married with a structured family life, with a 
history of alcohol ingestion greater than 100 g/day since the age of 30 in the context of 
social drinking and accompanying meals, presented with edema of the right foot one 
month prior to hospital admission. At this time the patient was observed by his family 
physician, and upon investigation, an altered hepatic profile was the only significant 
finding. The patient claimed to have ceased his alcohol consumption at this point in 
time. Previous analytical studies dating as far back as 2002, registered elevated liver 
enzymes, with a predominance of ALAT over ASAT, however, the patient was not 
alerted to this fact by his family practitioner.      
 Two weeks after the initial foot edema, the patient noted bilateral edema of the 
legs and a marked increase in abdominal perimeter, without the perception of jaundice 
by the patient himself or family members. The patient sought medical attention upon 
onset of these symptoms and was medicated with furosemide and spironolactone. After 
4 days of treatment with diuretics with no medical improvement, the patient was 
admitted to the hospital for further investigation. Upon admission, laboratory findings 
exhibited a total bilirubin of 12.2 mg/dL (normal range, 0.2-1.2 mg/dL), ASAT of     
351 U/L (normal range, 5.0-34.0 U/L), ALAT of 202 U/L (normal range, < 55.0 U/L), a 
hemoglobin value of 12.5 g/dL (normal range, 13.0-18.0 g/dL), a platelet count of 
151000/μL (normal range, 150000-400000/μL), a leucocyte count of 7700/μL (normal 
range, 4000-11000/μL), a C-reactive protein of 4.12 mg/dL (normal range, < 0.50 
mg/dL), and an INR of 3.4. Imaging tests also performed at this time depicted a pattern 
compatible with cirrhosis.  
Having excluded a potential spontaneous bacterial peritonitis and pondering the 
possibility of being in the presence of an acute alcoholic hepatitis, with an elevated 
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Maddrey discriminant function score of 142, medical professionals initiated corticoid 
treatment with prednisolone (40 mg/day). The patient, however, was not responsive to 
corticosteroid treatment in accordance with the Lille criteria at the 7 day mark, having a 
documented score of 0.995. The deteriorating clinical picture with progressive increase 
of bilirubin levels, further worsening of the coagulation profile and the appearance of 
grade I encephalopathy, prompted the medical team to transfer the patient to a liver 
transplantation hospital of reference in Oporto (CHP-HSA) 12 days after initial hospital 
admission, under the diagnosis of acute alcoholic hepatitis.    
 On arrival at that institution, the patient was vigil and oriented, however, slightly 
sluggish. There was no evidence of flapping. On physical examination, the patient 
presented with jaundice, hydrated mucosa, spider veins on torso and atrophy of 
temporal muscles. His blood pressure was documented at 151/72 mmHg with a pulse of 
102 beats per minute, and he was afebrile. Upon pulmonary auscultation, vesicular 
murmur was diminished at pulmonary bases and no audible heart murmurs were found 
on cardiac exam. On inspection of the abdomen, large volume ascites was present 
without tension or pain. Discrete edema of pretibial and malleolar regions was also 
noted. One day following admission, the patient was admitted into the intermediate care 
unit and also underwent a transjugular biopsy which confirmed the diagnosis of acute 
alcoholic hepatitis in context of preexisting cirrhosis. There was no evidence of sepsis 
and portal thrombosis was also excluded. Within 3 days, there was frank deterioration 
of the patient’s clinical picture, rapidly progressing from grade II encephalopathy to 
grade III encephalopathy, with further worsening of the coagulation disorder and renal 
function. At this point in time the patients MELD score was calculated to be 39.  
 The patient was consequently transferred to the intensive care unit this same day 
and a hepatic transplant was proposed, with indication for molecular adsorbents 
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recirculation system as a means of bridging the gap until actual transplant. 
Subsequently, the patient received a hepatic transplant 2 days later.  
On the days following the procedure, the patient began to present with hepatic 
ischemia with poor prognosis as documented on surgical transcripts, consequently being 
subjected to 2 further surgical interventions. Four days following the transplant, 
however, the patient succumbed to the post-operative complications and died due to 
multi-organ failure. 
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Discussion 
The severity of AAH is best assessed using the Maddrey DF (or more recently 
with the GAHS), which is reproducible and an unbiased criterion to predict the risk of 
early death in these patients.
26,31 A DF  ≥ 32 indicates high risk of early mortality in the 
absence of treatment.
31 
AAH is considered severe if the Maddrey DF  is greater than or 
equal to 32,  threshold for which initiating glucocorticoid treatment is also 
recommended.
2,13,28,34  
Thus, to reduce the probability of early death, patients with a DF 
≥ 32 need to be offered treatment.31 Upon consulting patient information we know that 
the patient in question had a presenting Maddrey DF of 142, having begun 
corticotherapy at this time. The standard medical care for severe hepatic insufficiency 
continues to be the administration of glucocorticoids (40 mg per day of prednisolone for 
at least 7 days),
14,35
 which also corresponds to what our patient was offered. In absence 
of treatment, spontaneous survival of patients with a DF ≥ 32 at 2 months is 50%,  in 
comparison to a spontaneous survival at 28-days in patients with a DF < 32 close to 
90%.
33  
When assessing the effect of the aforementioned corticotherapy, nonresponse to 
treatment is defined according to the Lille model as a score of 0.45 or greater after 7 
days of medical therapy, or a continuous increase in the Model for End-Stage Liver 
Disease (MELD) score, reflecting an early worsening of liver function.
14, 28-29 
Medical 
reports confirm that the patient was a non-responder in accordance with the Lille model 
and eventually progressed to a MELD score of 39. In responders, the beneficial effect of 
corticosteroids renders other treatment options unnecessary.
33 
Conversely, non-
responders to corticosteroids have a poor survival rate and require new strategies.  
Recently, it was observed that non-responders show a strong resistance profile to 
various medications, including pentoxifylline.
33 
Even though corticosteroids are 
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efficient in severe AAH to improve short-term survival, new treatment options are 
indeed required to improve the probability of being alive within the year following the 
onset of disease.
15          
The study conducted by Yu et al. (2010) demonstrated that the mortality rate of 
alcoholic hepatitis patients is positively correlated with the severity of the disease. The 
pooled analysis also showed that hepatic failure, gastrointestinal bleeding and infection 
were the 3 main causes of early death of alcoholic hepatitis patients.
1,15 
The high risk of 
early death  in patients with severe AAH not responding to medical therapy makes it 
necessary to consider all available treatment options, including transplantation, in 
targeted patients.
29
 According to Mathurin et al. (2011) patients whose alcoholic 
hepatitis is not responding to medical therapy have a 6-month survival rate of 
approximately 30%.
29
 Being that most alcoholic hepatitis deaths occur within 2 months, 
early liver transplantation is an appealing option, although still fairly controversial.
29 
In regards to transplantation in ALD patients, approximately 85% of the 
transplant programs in the United States require 6  months of abstinence prior to the 
procedure,
29,31
 with about 75% of centers expecting patients to sign a formal contract to 
that effect.
33
  However, despite the frequent use of the 6 month rule, in 2005 the UNOS 
and the French Consensus Conference on liver transplant in view of absence of enough 
evidence to support the 6 month sobriety rule no longer consider it to be a formal 
guideline.
29,33             
In the study conducted by Mathurin and colleagues, patients with severe AAH, 
without meeting the 6 month abstinence period, were selected from 7 centers for early 
liver transplantation.
29
 Those selected for hepatic transplant had to meet various 
prerequisites.  In addition to being non-responders, the following criteria also had to be 
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met: no prior episodes of AAH and no severe coexisting conditions, well integrated 
individual with an active role in the community, excellent support group with 
supportive family members, as well as a commitment to alcohol abstinence.
29 
These 
same patients also needed to earn the consensus of the multidisciplinary group assessing 
their case. Upon applying such criteria, fewer than 2% of patients defined as non-
responders to corticotherapy were recruited at the various centers, elucidating the 
stringency of such selection criteria.
29
 The patient presented in our case report fulfilled 
all the criteria set by Mathurin et al. (2011) in regards to the eligibility for hepatic 
transplant in individuals with AAH. We can conclude that in relation to prerequisites 
the patient was correctly selected for the procedure. 
    
Although patients meet a strict number of criteria and are put through a rigorous 
selection process, there is still some reluctance in listing these patients for hepatic 
transplant. The perception that patients with ALD have played a significant role in their 
illness seems to be a contributing factor to the negative view of such patients.
21 
Much of 
the hesitancy to list patients for orthotopic liver transplantation (OLT) in the setting of 
acute alcoholic hepatitis arises from concern that patients will return to drinking and 
concern about inappropriately transplanting a patient who may recover with medical 
therapy.
8 
 The reluctance to perform transplantation in patients with alcoholism can 
therefore often be summed up by two general ideas: that these patients are responsible 
for their illness and that they are likely to resume alcohol use after transplantation.
31
 
Although numerous studies have lent support to the validity of the sobriety 
period, they have also observed that the enforcement of this period alone delays listing 
for transplantation in a considerable number of candidates with a low probability of 
relapse.
21,29
 Indeed, the duration of abstinence before transplantation is a poor indicator 
of the likelihood of remaining abstinent after transplant,
8,22,29 
and the price of insisting 
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on a fixed abstinence period may be equivalent to death in some patients.
8,21-22,30,36
 
Therefore, in facing such a dismal outcome, hepatic transplant might be considered 
appropriate in null responders selected using criteria such as absence of other 
comorbidities, social integration and the existence of family members able to support 
the patient through liver transplantation programme,
27 
even without meeting the 6 
month abstinence mark, as confirmed by the study conducted by Mathurin et al. (2011).
 
While isolated cases of relapse with consequent damage to the graft have been 
recorded, most studies have found that alcoholism relapse leading to allograft injury is a 
relatively unusual complication among those patients with alcoholism who are selected 
for hepatic transplantation.
32
 Even in cases of relapse, studies have reported similar 1 
and 5 year survival rates for patients undergoing OLT for ALD in comparison with 
other indications, and in most studies alcohol relapse also did not influence 1 and 5 year 
rates after OLT for ALD alone.
13,31
        
Even though there is strong evidence to support OLT in AAH,  medical and 
ethical concerns about the appropriate use of scarce resources and the degree of priority 
given to patients with ALD continues to be a controversial issue.
31 
The ever increasing 
demand for donor organs and the inadequate rate of organ donation, combined with the 
concern that alcoholic patients might relapse to drinking, thereby damaging the 
transplanted liver, has been a large deterrent.
31
 The limited supply of donor organs 
frequently biases what should be equal access to potential medical benefits for all 
patients.
29      
    
 Modifications in guidelines for hepatic transplantation in patients with 
alcoholism may conflict with public preferences for liver-transplant allotment and may 
decrease public willingness to donate.
29
 Interestingly, this has not occurred in response 
to transplantation being offered to patients with fulminant hepatic failure due to 
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voluntary acetaminophen poisoning,  nor to intravenous-drug users with acute hepatitis 
B virus infection.
28,36 
In fact, the European Association for the Study of the Liver 
(EASL) already consider OLT as a treatment option in highly selected patients in their 
recent clinical practical guidelines on the management of alcoholic liver disease.
9
 It is 
thus vital that the public are made aware that patients are only offered transplantation if 
they fail to recover after a period of abstinence and medical treatment and that the 
incidence of significant post-transplant recidivism is low.
21 
 
The continuing imbalance between the few available livers and the increasing 
numbers of patients on waiting lists has led physicians to develop prognostic factors to 
determine disease severity in order to list and allocate donor organs to the sickest 
patients.
37 
Among available scores, the MELD is now considered the gold standard 
when selecting candidates for liver transplantation.
38-39  
Optimal timing for liver 
transplantation in alcoholic patients varies drastically between transplant programs, and 
decisions on transplant eligibility should be made on an individual basis, with careful 
prediction of short-term survival.
33 
An American conference held in 2003 stated that the 
Model for End-Stage Liver Disease meets the goal of providing a system that 
emphasizes the urgency of the candidate.
33 
Candidates with a MELD score < 15 had a 
lower mortality risk than transplanted patients with a similar MELD score.
33
 With 
scores of 18-20, studies show the mortality risk was lower among transplant recipients 
when compared with candidates.
39 
Survival benefit increased with increasing MELD 
score with recommendations stating that the best option is to list patients with a MELD 
score  ≥ 15.37 Some investigators, however, have suggested that a cutoff point at 40 may 
be used to define a patient as too ill for liver transplantation.
33 
Nonetheless, although 
recipients with a MELD score ≥ 40 had greater post-transplant mortality, their survival 
rate was still greater than that for candidates who were not transplanted.
39 
According to 
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the study conducted by Mathurin et al. (2011), the cumulative 6-month survival rate 
(±SE) was higher among patients who received early transplantation than among those 
who did not (77±8% vs. 23±8%).
29
 Our patient at time of transplant proposal had a 
MELD score of 39. Even though we have ascertained that regardless of the high MELD 
score, transplanted patients in those cases continue to have a higher survival rate in 
comparison to those not transplanted, we can speculate that the negative outcome and 
consequent death in our patient could have been predicted based on the severity pre-
transplant as denoted by the MELD score.        
With exception of those patients considered to be too ill, the outcome for 
patients who undergo transplantation for ALD is similar to that seen in patients 
transplanted for other forms of end-stage chronic liver disease.
22,30 
The study conducted 
by Tome et al. (2002) clearly demonstrated that survival after liver transplantation in 
patients with alcoholic cirrhosis plus alcoholic hepatitis detected in explanted liver was 
similar to that of patients transplanted for non-alcoholic disease.
40 
In addition, it is 
known that ALD patients post OLT have reduced incidence of acute cellular rejection.
31 
Chronic ductopenic rejection is also reportedly less common or the same in the patients 
receiving OLT for ALD from those for other indications.
31   
  
 Infections, on the other hand, are reportedly more common following OLT in 
patients with ALD. The incidence of bacterial infections is greater in these patients 
while the incidence of cytomegalovirus infection is comparable to those patients 
transplanted for non-alcoholic liver disease.
31  
Mathurin et al. (2011) reported that 5 of 
the 6 deaths post-transplant of a total of 26 case patients, were premature and a 
consequence of infection, 4 deaths of which were attributed to invasive aspergillosis.
29 
Even before transplantation, infection appears to be a consequence of absence of 
improvement in liver function, as assessed by response to therapy.
41 
In addition, we can 
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not rule out the brief course of corticotherapy in non-responders as a contributing factor, 
at least in part, to susceptibility to infection.
41 
Studies evaluating the usefulness of 
fungal prophylaxis as well as prophylactic antibiotics before transplantation, duration of 
glucocorticoid use before and after transplantation, and the tailoring of 
immunosuppressive regimens
29,41
 are needed in order to develop possible strategies for 
improving outcome in face of infection. Sequential screening for possible infections 
may also have some value in these patients.      
Choosing the appropriate moment for transplantation is in fact crucial. Optimal 
timing in regards to transplantation will be imperative in avoiding the adverse effects of 
intervening too early or too late. We can speculate that the patient presented in this case 
report, although considered to be the “perfect candidate”, was not transplanted within 
the ideal window of time, leading to additional complications post-transplant and 
consequently death.
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Conclusion 
The management of patients with alcoholic liver disease is a challenge. The high 
rate of mortality associated with severe AAH urges the need for more effective 
treatment options. Whereas corticotherapy may be of worth in those patients defined as 
responders, it is a different question when we discuss those that are defined as non-
responders. In this group of patients new therapeutic options are necessary. Hepatic 
transplant can be one of those options in selected patients that fulfill various criteria 
including the absence of other comorbidities, social integration and the existence of a 
strong support group. The recent EASL clinical practical guidelines on the management 
of alcoholic liver disease already consider OLT in highly selected patients, altering the 
paradigm regarding the conduct and treatment of AAH.    
 Alcoholic hepatitis is indeed an acceptable indication for liver transplant, as 
survival in well selected patients after transplantation is similar to those seen in patients 
who receive grafts for other causes. Relapse to heavy drinking is uncommon and as yet, 
has not shown to adversely affect outcome. At present, there is no evidence to deny 
liver transplantation to patients with shorter periods of abstinence based on either poorer 
survival or higher relapse rate. Decisions on transplant eligibility, however, should be 
made on an individual basis, as patient selection is important for rationing scarce 
organs.           
Although more data are required, the benefit of OLT in patients with severe 
AAH who fail to respond to corticotherapy is a promising area of research. While this is 
true, early liver transplantation is relevant only for a minority of patients whereas new 
therapeutic strategies are urgently needed for the majority of non-responders. As well, 
we need to better define the optimal timing to transplant eligible patients. In addition to 
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timing, new measures must also be considered in order to circumvent possible 
infections post-transplant in these patients.   
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Appendix 
Transplante Hepático na Hepatite Aguda Alcoólica: Resumo 
A doença hepática alcoólica é um problema de saúde global. A doença hepática 
crónica com progressão para a cirrose e suas complicações inerentes são o segundo 
motivo mais frequente de transplante hepático na Europa e nos Estados Unidos. Em 
geral, o risco de desenvolver doença hepática está associado ao padrão de ingestão, tipo 
de bebida ingerida, e a quantidade de álcool consumido. A ingestão de álcool durante 10 
ou mais anos com doses em excesso de 40-80 g/dia no sexo masculino e 20-40 g/dia no 
sexo feminino, são geralmente necessárias para provocar doença hepática alcoólica. No 
entanto, as actuais directrizes europeias referem que mesmo pequenas quantidades de 
álcool ingerido (inferior a 25 g/dia) pode ser suficiente para induzir a doença hepática 
alcoólica. A raça, bem como a obesidade, sobrecarga de ferro, infecção concomitante 
com hepatite viral e factores genéticos, entre outros, também podem estar implícitos. A 
doença hepática alcoólica engloba uma síndrome clínica distinta induzida pelo consumo 
de álcool. Esta síndrome é conhecida por hepatite aguda alcoólica e tem um espectro 
clínico amplo que vai desde assintomático até às alterações analíticas, insuficiência 
hepática e morte. Estima-se que aproximadamente 35% dos alcoólicos sofrem de 
hepatite aguda alcoólica, sendo que a maioria dos casos ocorrem antes dos 60 anos de 
idade.  
O diagnóstico de doença hepática alcoólica baseia-se numa combinação de 
características, incluindo uma história de consumo de álcool significativa, evidência 
clínica de doença hepática e alterações laboratoriais típicas. A hepatite aguda alcoólica 
está associada a um quadro clínico vasto, com astenia, dor no hipocôndrio direito, febre 
e taquicardia, e normalmente com icterícia. Caracteristicamente, a proporção de 
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aspartato aminotransferase para alanina aminotransferase é de aproximadamente 2:1 e, 
habitualmente encontram-se em níveis não muito elevados. Outras alterações 
laboratoriais comuns na hepatite aguda alcoólica incluem a hiperbilirrubinemia, 
leucocitose e anemia.  
Com uma mortalidade aos 28 dias de até 50%, terapêutica eficaz nestes casos é 
essencial. Para além do suporte nutricional e garantir a abstinência destes doentes, os 
corticosteróides permanecem como terapêutica de primeira linha na prática clínica. A 
administração de corticóides é preconizada em doentes que tenham um factor 
discriminador de Maddrey superior ou igual a 32. Recentemente, o score de Glasgow 
para a hepatite alcoólica revelou-se como sendo preditivo da gravidade da doença e de 
indicação para iniciar corticoterapia para valores superiores ou iguais a 9. A 
administração de 40 mg por dia de prednisolona durante pelo menos 7 dias constitui o 
padrão terapêutico. O score de Lille irá posteriormente avaliar a resposta à 
corticoterapia após 7 dias, dando indicação de quais os doentes que respondem e, 
portanto, beneficiam da manutenção do corticóide em comparação com aqueles que não 
obtiveram resposta. Ao avaliar o efeito da referida corticoterapia, não-respondedores 
são definidos com uma pontuação de 0,45 ou superior após 7 dias de terapêutica 
médica, de acordo com o modelo de Lille. Nos doentes que não respondem, esta 
terapêutica não aumentará a sobrevida a longo prazo, e assim, novas estratégias 
terapêuticas são necessárias. Será nestes casos que podemos olhar para o transplante 
hepático como uma opção possível de tratamento para melhorar a sobrevida neste grupo 
de doentes.           
O transplante hepático em doentes com hepatite aguda alcoólica, no entanto, 
permanece um assunto bastante controverso entre a comunidade de profissionais de 
saúde e do público. Existe uma relutância em disponibilizar os órgãos escassos para 
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transplante a doentes que o público habitualmente percepciona como tendo infligido em 
si a sua doença decorrendo de um comportamento voluntário e nocivo. Inclusive, a 
preocupação de que os doentes poderão vir a sofrer de uma recaída após o transplante, 
contribuiu para a implementação de um período obrigatório de 6 meses de abstinência 
alcoólica, necessária para que tais doentes viessem a ser considerados para transplante 
hepático em alguns países. Contudo, vários estudos indicam que a duração da 
abstinência prévia ao transplante é um indicador pobre do risco de recaída após o 
transplante. Para além disso, sabemos que estamos perante doentes cuja regra dos 6 
meses de abstinência não deverá ser aplicável, dado que, a maioria dos doentes graves 
abstinentes morrem antes desse período devido à gravidade da situação clínica.  
 Recentemente existem vários estudos que apontam para a necessidade de definir 
novos critérios de inclusão destes doentes, não necessitando de cumprir o período de 6 
meses de abstinência. Os critérios de selecção para transplantação de doentes com 
hepatite aguda alcoólica, de acordo com o estudo de Mathurin et al. (2011), incluem a 
hepatite aguda alcoólica como o primeiro episódio de descompensação da doença 
hepática, ausência de outras co-morbilidades, integração social e a existência de um 
grupo de apoio, para além do candidato reunir o consenso dos profissionais envolvidos 
no processo da decisão clínica. De facto, as recentes orientações clínicas da Associação 
Europeia para o Estudo do Fígado já consideram o transplante hepático como possível 
terapêutica em doentes altamente seleccionados.      
O modelo para a doença hepática terminal conhecido por MELD, cumpre o 
objectivo de fornecer um sistema que enfatiza a urgência dos candidatos em termos de 
necessidade de terapêutica. Um doente com uma pontuação de MELD inferior a 15 tem 
um risco menor de mortalidade em comparação com doentes transplantados com a 
mesma pontuação. Os estudos demonstram que pontuações de MELD ente os 18-20 
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valores estão associados a menor risco de mortalidade nos doentes que forem 
submetidos a transplantação em comparação com candidatos que não forem 
transplantados. A sobrevida aumenta com o aumento da pontuação de MELD e 
recomenda-se a listagem de doentes para transplante com uma pontuação de MELD 
superior ou igual a 15.         
 Alguns investigadores, no entanto, sugerem que deverá existir um ponto de 
limite para definir um doente que estará demasiado doente para ser submetido a um 
transplante. Contudo, apesar de recipientes com uma pontuação de MELD superior ou 
igual a 40 terem uma maior taxa de mortalidade pós-transplante, a sua taxa de sobrevida 
continua maior pós-transplante em comparação com os candidatos que não foram 
submetidos à transplantação. Escolher o momento adequado para o transplante é de 
facto crucial. O momento ideal em relação ao transplante é imperativo para evitar os 
efeitos adversos de intervir demasiado cedo ou demasiado tarde.    
De acordo com vários estudos, podemos concluir que a hepatite aguda alcoólica 
pode ser uma indicação aceitável para transplante hepático, com taxas de sobrevivência 
pós-transplante, em doentes bem seleccionados, semelhantes às observadas em doentes 
transplantados por outras etiologias. A recaída pós transplante é incomum e quando 
ocorre não demonstrou afectar adversamente os resultados a prazo de um e cinco anos 
pós transplantação. Actualmente, portanto, não há nenhuma evidência para negar o 
transplante hepático a doentes com base em períodos mais curtos de abstinência ou por 
maior taxa de recaídas e consequente lesão do fígado transplantado.  
 A incidência de infecções bacterianas, contudo, é maior em doentes 
transplantados por doença hepática alcoólica, enquanto a incidência de infecção por 
citomegalovírus é comparável com as taxas observadas em doentes transplantados por 
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doença hepática não alcoólica. Deveremos, portanto, estar atentos a esta ocorrência em 
doentes após a transplantação. 
Apesar de serem necessários mais estudos, o benefício de transplantação em 
doentes com hepatite aguda alcoólica grave que não respondem a corticoterapia é uma 
área de estudo promissora. Apesar de se evidenciar este benefício, o transplante 
hepático precoce é relevante em apenas uma minoria de doentes, e portanto, novas 
estratégias terapêuticas são urgentemente necessárias para a maioria de doentes não-
respondedores à corticoterapia.        
 Necessitamos, ainda, de melhor definir o momento ideal para a transplantação 
em doentes elegíveis. O reconhecimento da janela de oportunidade óptima é essencial 
para podermos intervir da forma a obter os melhores resultados possíveis. Novas 
medidas devem, também, ser consideradas a fim de contornar possíveis infecções pós-
transplante nestes doentes. Estudos avaliando a utilidade da profilaxia fúngica, bem 
como antibióticos profilácticos prévios ao transplante, a duração da utilização de 
corticosteróides, antes e após o transplante, e o acerto de regimes de imunossupressão, 
irão ser necessários a fim de desenvolver estratégias possíveis para melhorar os 
resultados em face da infecção nestes doentes.       
No caso clínico apresentado foi proposto abordar o caso de um doente de 56 
anos de idade com hepatite aguda alcoólica, não respondedor à terapêutica com 
corticóides, com uma história pregressa de alcoolismo em contexto social desde os 30 
anos de idade. O papel da transplantação hepática em contexto de ingestão de álcool e 
as implicações éticas inerentes que advêm da realização deste procedimento ainda não 
consensual são discutidos em redor deste doente.     
 Um mês anterior ao internamento, o doente apresentou com edema do pé direito, 
evoluindo para edema bilateral dos membros inferiores em associação com um aumento 
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do perímetro abdominal correspondente a ascite duas semanas após o início do quadro 
clínico.           
 Na admissão ao hospital foram evidenciadas alterações analíticas marcadas, 
incluindo um aumento das transaminases hepáticas, hiperbilirrubinemia, anemia e 
alterações do perfil da coagulação, para além de um factor discriminador de Maddrey 
elevado. O doente foi nesta altura medicado com prednisolona, mas posteriormente 
rotulado como não-respondedor de acordo com o score de Lille. Com a continuada 
degradação do estado clínico do doente, este foi transferido para um hospital de 
referência na transplantação hepática. Aqui, já apresentava com ligeiras alterações da 
consciência, icterícia, ascite de grande volume, e ainda, ligeiro edema pré-tibial e 
maleolar. A biópsia transjugular efectuada nesta altura confirmou o diagnóstico de 
hepatite aguda alcoólica em contexto de uma cirrose preexistente.   
 Ao nível que o estado clínico do doente veio a piorar, com encefalopatia de grau 
II rapidamente progredindo para encefalopatia de grau III, com uma pontuação de 
MELD elevada, o doente foi proposto para a transplantação hepática. O doente satisfez 
os critérios enumerados pelo estudo de Mathurin et al. (2011). Contudo, após a 
transplantação, o doente eventualmente cedeu a um número de complicações e morreu 
por falência multiorgânica.         
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abstinência alcoólica. 
 
 
